drugset
drugset / Trial / NCT06569147

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

NCT06569147 ↗

Phase 1/2 Recruiting 49 enrolled Brigham and Women's Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.

Timeline

Start
2024-11-01
Primary completion
2027-09-01
Completion
2029-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Elranatamab Monoclonal antibody 76 mg Subcutaneous

Indications

AL amyloidosis